

PATENT SPECIFICATION

(11) 1 432 649

1 432 649

(21) Application No. 42173/73 (22) Filed 7 Sept. 1973
 (23) Complete Specification filed 23 July 1974
 (44) Complete Specification published 22 April 1976
 (51) INT CL² C07D 237/28; A61K 31/495; C07D 491/04//C07D
 491/04, 237/28, 317/48)



(52) Index at acceptance

C2C 134X 1504 1592 1772 200 213 215 21X 220 226 22Y 246
 247 250 251 252 255 25Y 305 30Y 351 352 364 366
 368 36Y 386 387 388 389 40Y 491 624 625 628 635
 658 65X 662 672 699 760 761 762 776 778 790 79Y
 TR TY WD ZG
 A5B 292 295 29Y 383 386 38Y 39X 441 44Y 482 48Y 503
 50Y 550 552 55Y 575 576 57Y 586 58Y 616 61Y 640
 644 64Y 661 66Y 77Y


(72) Inventor GERAINT JONES

(54) NEW CINNOLINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS

(71) We, IMPERIAL CHEMICAL INDUSTRIES LIMITED, Imperial Chemical House, Millbank, London SW1P 3JF, a British Company, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to heterocyclic compounds, and more particularly it relates to new cinnoline derivatives which are active as inhibitors of the effects following the combination of reagin-like antibodies and their antigens.

According to the invention there are provided cinnoline derivatives of the formula:—



wherein R¹ stands for hydrogen or a C₁₋₆-alkyl radical, R² stands for hydrogen or a C₁₋₅-alkyl, C₃₋₅-alkenyl or benzyl radical, and R³ stands for hydrogen or a methylenedioxy, C₁₋₅-alkyl, C₁₋₅-alkoxy, phenyl or benzyloxy radical, and non-toxic pharmaceutically-acceptable salts thereof.

Suitable values for R¹ are, for example, hydrogen or a methyl, ethyl or isopropyl radical. Suitable values for R² are, for example, hydrogen or a methyl, ethyl, allyl or benzyl radical. Suitable optional substituents (R³) include, for example, a methylenedioxy, methyl, ethyl, n-propyl, isopropyl, methoxy, isopropoxy, phenyl or benzyloxy radical. It is to be understood that the two bonds of the methylenedioxy radical (R³) are attached to adjacent carbon atoms of the benzene ring.


Suitable salts of the invention in the case where the compound of the formula I is sufficiently basic are acid-addition salts derived from inorganic or organic acids which afford non-toxic pharmaceutically-acceptable anions, for example hydrochlorides. Suitable salts in the case where the compound of the formula I is sufficiently acidic are salts in which the said compound provides the anion and the cation is non-toxic and pharmaceutically-acceptable. Examples of such salts are ammonium, alkali metal, alkaline earth metal or aluminium salts, or salts with non-toxic pharmaceutically-acceptable organic bases, for example triethanolamine or ethylenediamine.

Preferred compounds of the invention are ethyl 6-ethyl-1-methyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionate, 6-ethyl-4-oxo-1,4-dihydrocinnoline-3-ylpropionic acid and its ethyl ester, and 6-n-propyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid.

15 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 96

According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R¹ and R² stand for hydrogen and R³ has the meaning stated above, and non-toxic pharmaceutically-acceptable salts thereof, which comprises reacting a benzazocine derivative of the formula:—

5




wherein R³ has the meaning stated above, with an alkyl nitrite and an inorganic acid in the presence of a small amount of water.

A suitable alkyl nitrite is, for example, n-butyl nitrite. A suitable acid is, for example, hydrochloric or sulphuric acid. The reaction is conveniently carried out in an inert organic solvent, for example an ether, for example 1,2-dimethoxyethane. The amount of water used in the reaction mixture is not critical; we have found that approximately 0.5—0.6% by volume gives satisfactory results.

10

Many of the said benzazocine derivatives are new compounds and they may be obtained by the following reactions:—

15



The phenylhydrazine derivatives (III), wherein R³ has the meaning stated above, may be obtained by standard synthetic procedures. Heating one of these compounds with cyclopentanone (IV) in the presence of dilute sulphuric acid, or heating the hydrochloride of one of these phenylhydrazine derivatives with cyclopentanone, affords the corresponding indole derivative of the formula V. Treatment of the latter compound at room temperature with sodium periodate in a mixture of methanol and water, together with tetrahydrofuran if there are solubility problems, affords the product of the formula II.

20

According to a further feature of the invention there is provided a process for the manufacture of the esters of the formula I wherein R¹ stands for a C₁₋₆-alkyl radical, R² stands for hydrogen, and R³ has the meaning stated above, and non-toxic pharmaceutically-acceptable salts thereof, which comprises esterifying the corresponding carboxylic acid wherein R¹ stands for hydrogen, or a corresponding acid halide or anhydride.


25

Any of the standard esterification procedures may be used, for example reacting the carboxylic acid with a C₁₋₆-alkanol in the presence of hydrogen chloride at about 50 to 150°C., for example under reflux.

30

According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R¹ stands for a C₁₋₆-alkyl radical, R² stands for C₁₋₅-alkyl, C₃₋₅-alkenyl or benzyl radical, and R³ has the meaning stated above, and non-toxic pharmaceutically-acceptable salts thereof, which comprises reacting an alkali metal derivative of the formula:—


35



wherein R¹ and R³ have the meanings stated immediately above and M stands for a sodium or potassium atom, with a halide reactant of the formula R²Hal, wherein R² has the meaning stated immediately above and Hal stands for a chlorine, bromine or iodine atom.

5 As a suitable halide reactant there may be mentioned, for example, methyl iodide, ethyl bromide, allyl bromide or benzyl chloride. The reaction is conveniently carried out in an organic solvent, for example dimethylformamide, at room temperature or at a moderately elevated temperature, for example 60—70°C. The alkali metal derivatives used as starting material may be obtained 5
10 by reacting the corresponding compound wherein R² stands for hydrogen with the hydride or amide of sodium or potassium, in a dry inert solvent, for example dimethylformamide, at room temperature.

10 The compounds of the formula I wherein R¹ stands for hydrogen and R² and R³ have the meaning stated above, and non-toxic pharmaceutically-acceptable salts thereof, may be obtained by hydrolysing a compound of the formula:— 10
15



wherein R² and R³ have the meanings stated above and Cy stands for an alkoxy carbonyl, phenyl alkoxy carbonyl, phenoxy carbonyl, cyano, carbamoyl (—CONH₂) or thiocarbamoyl (—CSNH₂) radical.

20 The hydrolysis is carried out in the presence of water. An organic solvent, for example dioxan or ethanol, may optionally also be present. A suitable hydrolytic agent is, for example, an alkali metal hydroxide, for example sodium hydroxide, or an inorganic acid, for example hydrochloric or sulphuric acid.

25 The esters of the formula VII may be obtained as described above, and the other starting materials of the formula VII may be obtained by the adaptation of known synthetic procedures.

The salts of this invention may be obtained by means of standard salt-making procedures.

30 The above-mentioned activity of the compounds of this invention has been demonstrated by their ability to inhibit, in the rat, passive cutaneous anaphylaxis induced by reaginic antibodies to egg albumin, using *B. pertussis* as an adjuvant. This is a known pharmacological test. The activity of individual compounds of this invention in the test depends upon their precise chemical structure, but generally speaking the compounds show activity in the test at a dose in the region 1—20 30
35 mg./kg. No toxic effects or undesirable side effects have been observed with the compounds at doses at which they are active in the said test.

40 When a compound of the invention is used in a warm-blooded mammal, for example man, for the treatment of a disease or syndrome which is initiated by an antigen-antibody reaction, for example allergic asthma, hay fever, urticaria or an auto-immune disease, it is recommended that said compound be administered orally or by inhalation at a dose of 0.01 mm./kg. to 1 mm./kg. at appropriate intervals, for example at 6-hourly intervals during the day. Alternatively, the said compound may be administered intravenously at a total daily dose of about 25 mg. per man.

45 According to a further feature of the invention there are provided pharmaceutical compositions comprising a compound of the formula I, wherein R¹, R² and R³ have the meanings stated above, or a non-toxic pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.

50 The pharmaceutical compositions of the invention are obtainable by well known methods using conventional diluents or carriers. The compositions may be in a form suitable for administration by inhalation. Suitable compositions comprise a mixture of the active ingredient with a solid diluent or carrier, for example lactose, the said mixture being in fine particulate form suitable for administration from a powder inhalation device. Alternatively, the compositions may be administered by inhalation in the form of a suspension or solution in a suitable liquid, for example water or an aqueous or non-aqueous medium, using a conventional nebulizer or a pressurised container. Alternatively, the pharmaceutical compositions of the invention may be orally-administrable or

injectable formulations, for example compositions suitable for oral or intravenous administration, for example tablets, capsules or sterile aqueous solutions or suspensions.

5 The pharmaceutical compositions of the invention may contain, in addition to a compound of formula I or a non-toxic pharmaceutically-acceptable salt thereof, one or more known active ingredients selected from β -adrenergic stimulants, for example isoprenaline, adrenaline, orciprenaline or isoethacine, or a pharmaceutically-acceptable acid-addition salt thereof, for example a sulphate, and prostaglandins having bronchodilatory activity, for example prostaglandin E₁ or E₂, and phosphodiesterase inhibitors selected from the following compounds:—

10 (a) 3 - acetamido - 6 - methyl - 8 - n - propyl - s - triazolo[4,3-a] - pyrazine;
 (b) 2 - amino - 4,6 - di - C₁₋₄ - alkyl - 5 - oxo - 4,5 - dihydro - triazolo[1,5 - a] - pyrimidines, for example 2 - amino - 6 - methyl - 5 - oxo - 4 - n - propyl - 4,5 - dihydro - s - triazolo[1,5-a]pyrimidine;
 15 (c) theophylline and related 3,5 - di - C₁₋₄ - alkyl - xanthines; and
 (d) 6,8 - di - C₁₋₄ - alkyl - 5,6 - dihydro - 5 - oxo - triazolo[4,3-c]pyrimidines, for example 5,6 - dihydro - 5 - oxo - 6,8 - di - n - propyl - s - triazolo[4,3-c]pyrimidine.


20 The pharmaceutical compositions of the invention may contain from 1% to 50% by weight of a compound of formula I or a non-toxic pharmaceutically-acceptable salt thereof.

25 The invention is illustrated by the following Examples:—

Example 1.

25 A suspension of 4,5-dihydro-1H,3H-1-benzazocine-2,6-dione (1 g.) in 1,2-dimethoxyethane (20 ml.) and water (0.1 ml.) was prepared, and freshly-prepared n-butyl nitrite (0.84 g.) was added. Hydrogen chloride gas was bubbled through the mixture at 25°C. for 5 minutes, and the resulting solution was stirred overnight at room temperature. The solution was then diluted with water (10 ml.), the mixture warmed for 5 minutes on a steam bath, and the resulting mixture filtered. The solid residue was recrystallised from aqueous ethanol, and there was thus obtained 4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid, m.p. 226—8°C.

30 In a similar manner, using the appropriate substituted benzazocine derivative as starting material, the following compounds were obtained:—



| R ³ | Crystallisation solvent | m.p. (°C.) |
|-----------------------|--|---------------|
| 6-Et | aqueous ethanol | 240—1 |
| 6-n-Pr | aqueous acetic acid | 230—1 |
| 6-iso-Pr | product not crystallised, but isolated by acidification of sodium salt with concentrated hydrochloric acid | 228—30 |
| 6-PhCH ₂ O | ethanol | 245—7 |
| 6-MeO | aqueous ethanol | 256—8 |
| 6-iso-PrO | aqueous acetic acid | 210—3 |
| 6-Ph | aqueous acetic acid | 306—10 (dec.) |

The 8-ethyl-4,5-dihydro-1H,3H-1-benzazocine-2,6-dione used as starting material for the preparation of the above-mentioned 6-ethyl derivative was obtained as follows:—

(a) To a suspension of 4-ethylaniline (90 g.) in water (280 ml.) was added concentrated hydrochloric acid (38% w/w, 280 ml.), and the mixture was warmed on a steam bath. The suspension obtained was stirred and cooled to 0°C., and a solution of sodium nitrite (52.1 g.) in water (180 ml.) was added during 45 minutes, the temperature being maintained at -10° to -5°C. by cooling. The dark solution was stirred at 0°C. for a further 30 minutes, and then filtered through "Celite" (the word 'Celite' is a registered Trade Mark). The filtered diazonium salt solution (stored at 0°C.) was added in portions to a stirred fresh mixture of sodium dithionite (500 g.) in ice-cold water (1 l.) keeping the temperature at 5—10°C. After the addition of each batch of the diazonium salt solution, further dithionite (total 500 g.) was added in portions. After the addition was complete (45 minutes), the mixture was stirred at room temperature overnight. The mixture was separated by filtration and the filtered solid was suspended in water (1 l.), basified with sodium hydroxide solution, and the mixture extracted with ethyl acetate (3 x 250 ml.). The combined extracts were washed with a minimum of water, dried ($MgSO_4$), and evaporated to give 4-ethylphenylhydrazine as a low melting solid. 5

(b) The above hydrazine derivative (80 g.) and cyclopentanone (50 g.) were mixed and heated on a steam bath for 15 minutes. A solution of concentrated sulphuric acid (40 ml.) in water (720 ml.) was added and the mixture was heated for a further 30 minutes. After cooling in an ice-bath, the black solid which separated was filtered off. A solution of the solid in toluene (750 ml.) was dried ($MgSO_4$) and filtered, and the filtrate was concentrated. The residue was applied to a silica gel column (1000 g.) Elution with toluene and concentration of the eluate gave 7-ethyl-1,2,3,4-tetrahydrocyclopentan[b]indole, m.p. 74—9°C. 10

(c) A solution of the above-mentioned indole derivative (50 g.) in methanol (1360 ml.) was added to a solution of sodium periodate (126 g.) in water (728 ml.) at room temperature. The solution became warm, and sodium iodate appeared as white needles. After 2 hours the mixture was diluted with water (500 ml.) and extracted with methylene dichloride (4 x 150 ml.). The combined extracts were washed with water (2 x 100 ml.), dried ($MgSO_4$), filtered, and evaporated to dryness. Crystallisation of the residue from toluene (including treatment with charcoal) gave 8-ethyl-4,5-dihydro-1H,3H-1-benzazocine-2,6-dione, m.p. 138—140°C. 15

The 8-benzyloxy-4,5-dihydro-1H,3H-1-benzazocine-2,6-dione used as starting material for the preparation of the above-mentioned 6-benzyloxy-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid was obtained as follows:—

(d) A solution of 4-benzyloxyphenylhydrazine hydrochloride (50.2 g.) and cyclopentanone (33.6 g.) in ethanol (150 ml.) was heated on a steam bath for 5 hours. The hot mixture was filtered and the filtrate evaporated to ca 750 ml., whereupon 7-benzyloxy-1,2,3,4-tetrahydrocyclopentan[b]indole, m.p., 110—2°C., crystallised. Evaporation of the mother liquor to dryness, chromatography of the residue on silica gel (600 g.), and elution with toluene, gave a further amount of the product, m.p. 114°C. 20

(e) A solution of the said 7-benzyloxy derivative (17.5 g.) in methanol (250 ml.) and tetrahydrofuran (100 ml.) was added to a solution of sodium periodate (28 g.) in water (130 ml.) at room temperature. The solution became warm and sodium iodate appeared as white needles. After 2 hours the solution was diluted with water (500 ml.) and extracted with methylene chloride (4 x 150 ml.). The combined extracts were washed with water (2 x 100 ml.), dried ($MgSO_4$), filtered, and evaporated. Crystallisation of the residue from toluene (including treatment with charcoal) gave 8-benzyloxy-4,5-dihydro-1H,3H-1-benzazocine-2,6-dione, m.p. 169—70°C. 25

The other benzazocine derivatives used as starting materials were obtained in similar manner. As indicated below, in one case the indole intermediate was obtained by procedure (b) above, and in the other cases by procedure (d) above, while in one case the benzazocine derivative was obtained by procedure (e) above, and in the other cases by procedure (c) above. 30

55


60

| Substituent in benzene ring | Indole derivative—procedure used | Benzazocine derivative—procedure used |
|-----------------------------|----------------------------------|---------------------------------------|
| n-Pr | d | c |
| iso-Pr | d | c |
| MeO | d | c |
| iso-PrO | d | c |
| Ph | b | e |

Example 2.

5 A suspension of 6-methyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid (1 g.) in methanol (10 ml.) was heated under reflux. Hydrogen chloride gas was bubbled through the mixture under reflux for 30 minutes. The mixture was then heated under reflux overnight. The mixture was cooled and diluted with water (50 ml.). The resulting mixture was filtered, and the solid residue was recrystallised from methanol. There was thus obtained methyl 6-ethyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionate, m.p. 173—4°C.

10 In a similar manner, starting with the appropriate propionic acid, there were obtained the following compounds:—




| R ¹ | R ³ | Crystallisation solvent | m.p. (°C.) |
|----------------|------------------------|-------------------------|---------------|
| Et | 6-Et | acetonitrile | 179—80 |
| iso-Pr | 6-Et | „ | 182—3 |
| Et | 6-n-Pr | „ | 175—7 |
| Et | 6-iso-Pr | „ | 155—60 (dec.) |
| Me | 6-iso-PrO | „ | 205—7 |
| Et | 6-iso-PrO | „ | 184—6 |
| Et | 6,7-OCH ₂ O | „ | 231—3 |
| Me | 6-Ph | methanol | 255—7 |
| Et | 6-Ph | ethanol | 202—3 |

15 Some of the propionic acids used as starting materials were obtained as described in Example 1, and the remainder were obtained by similar procedures.

Example 3.

Sodium hydride in oil (0.33 g.) was washed free from oil with petroleum ether (b.p. 40—60°C.; x 5 ml.) and then suspended in dimethylformamide (10 ml.) Ethyl 6-ethyl-4-oxo-1,4-dihydroxycinnolin-3-ylpropionate (1 g.) was added, and the mixture was stirred at room temperature for 15 minutes. Methyl iodide (0.5 ml.) was added, and the mixture was stirred at 60—70°C. for 2 hours. The mixture was cooled and poured into water (100 ml.), and the resulting mixture was filtered. The solid residue was crystallised from petroleum ether (b.p. 60—80°C.), and there was thus obtained ethyl 6-ethyl-1-methyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionate, m.p. 92—94°C.


The following compounds were obtained in a similar manner from the appropriate starting materials, except that, when the reaction mixture was poured into water (100 ml.), instead of being filtered, the mixture was extracted with diethyl ether (3 x 100 ml.), the combined extracts washed with saturated sodium chloride solution (100 ml.), dried ($MgSO_4$) and evaporated to dryness. The residue was crystallised using the solvents stated below. In this way, the following compounds were obtained:



| R ¹ | R ² | R ³ | Crystallisation solvent | m.p. (°C.) |
|----------------|-------------------|------------------------|--|------------|
| Et | allyl | 6-Et | pet.ether (b.p. 80—100°C.) | 80—2 |
| Et | Et | 6,7-OCH ₂ O | toluene-pet. ether (b.p. 60—80°C.) | 125—7 |
| Me | Me | 6-Ph | ethyl acetate-pet. ether (b.p. 60—80°C.) | 130—2 |
| Me | Me | 6-iso-Pro | toluene-pet. ether (b.p. 60—80°C.) | 124—6 |
| Et | PhCH ₂ | 6-Et | pet. ether (b.p. 60—80°C.) | 110—2 |

WHAT WE CLAIM IS:—

1. A cinnoline derivative of the formula:—



wherein R¹ stands for hydrogen or a C_{1—6}-alkyl radical, R² stands for hydrogen or a C_{1—5}-alkyl, C_{3—5}-alkenyl or benzyl radical, and R³ stands for hydrogen or a methylenedioxy, C_{1—5}-alkyl, C_{1—5}-alkoxy, phenyl or benzyloxy radical, or a non-toxic pharmaceutically-acceptable salt thereof.

2. A compound as claimed in claim 1 wherein R¹ stands for hydrogen or a methyl, ethyl or isopropyl radical, R² stands for hydrogen or a methyl, ethyl, allyl or benzyl radical, and R³ stands for hydrogen or a methylenedioxy, methyl, ethyl, n-propyl, isopropyl, methoxy, isopropoxy, phenyl or benzyloxy radical.


5 3. A salt as claimed in claim 1 or 2 in the case where the compound of the formula I is sufficiently basic, which salt is an acid-addition salt derived from an inorganic or organic acid which affords a non-toxic pharmaceutically-acceptable anion.

10 4. A salt as claimed in claim 1 or 2 in the case where the compound of the formula I is sufficiently acidic, in which salt the acid compound of the formula I provides the anion, and the cation is non-toxic and pharmaceutically-acceptable.

15 5. A compound as claimed in claim 1 or 2 which is either ethyl 6-ethyl-1-methyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionate, 6-ethyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid or its ethyl ester, or 6-n-propyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid.

6. A process for the manufacture of a compound of the formula I as stated in claim 1, wherein R¹ and R² stand for hydrogen and R³ has the meaning stated in claim 1, or a non-toxic pharmaceutically-acceptable salt thereof, which comprises reacting a benzazocine derivative of the formula:—

20




20

wherein R³ has the meaning stated in claim 1, with an alkyl nitrite and an inorganic acid in the presence of a small amount of water.

7. A process for the manufacture of a compound of the formula I as stated in claim 1, wherein R¹ stands for a C₁₋₆-alkyl radical, R² stands for hydrogen and R³ has the meaning stated in claim 1, or a non-toxic pharmaceutically-acceptable salt thereof, which comprises esterifying the corresponding carboxylic acid wherein R¹ stands for hydrogen, or a corresponding acid halide or anhydride.

8. A process for the manufacture of a compound of the formula I as stated in claim 1, wherein R¹ stands for a C₁₋₆-alkyl radical, R² stands for a C₁₋₅-alkyl, C₃₋₅-alkenyl or benzyl radical, and R³ has the meaning stated in claim 1, or a non-toxic pharmaceutically-acceptable salt thereof, which comprises reacting an alkali metal derivative of the formula:—



35 35 wherein R¹ and R³ have the meanings stated above and M stands for a sodium or potassium atom, with a halide reactant of the formula R²Hal, wherein R² has the meaning stated above and Hal stands for a chlorine, bromine or iodine atom.

9. A pharmaceutical composition comprising a compound of the formula I as stated in claim 1, wherein R¹, R² and R³ have the meanings stated in claim 1, or a non-toxic pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.

40 10. A compound as claimed in claim 1, substantially as described in any of the foregoing Examples.

R. ALLERTON,
Agent for the Applicants.